← Leaderboards
Yanan Zhang
Research Triangle Institute
$8,086,410
Attributed
$12,190,446
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,190,446 · 9
By mechanism
R01$8,121,769 · 4
R61$1,881,741 · 1
R21$1,087,334 · 2
R33$992,323 · 1
R03$107,279 · 1
Top collaborators
- Joyce Besheer3 shared
- Catherine M Kotz3 shared
- Rangan Maitra3 shared
- Jun-Xu Li1 shared
- Yuan-Xiang Tao1 shared
Most similar at Research Triangle Institute
Same institution · by research overlap
- Rangan Maitra$14,311,381
- Brian F Thomas$3,550,619
- Thuy Nguyen$804,287
Others in their field
Top investigators on “Agonist”
- John M Lachin · George Washington University$118,921,924
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Alan G. Barbour · University Of California Irvine$40,092,035
- Alexandros Makriyannis · University Of Connecticut Storrs$29,942,402
- Scott T Weiss · University Of California, San Diego$28,624,344
- John Didsbury · T3d Therapeutics, Inc.$25,150,614
Research focus
AgonistDoseReportingDrug KineticsPropertyIn VivoStructurePharmaceutical PreparationsAnimal ModelSignal TransductionIn VitroBehavioralPharmacologyReceptorSmall MoleculeRattusBrainLigandsEvaluationResponseDesignEndocannabinoidsProgramsSeries
Grant awards (22)
Reducing the post weight-loss energy expenditure gap with orexin agonists$672,884
R01 · FY2025 · DK
Allosteric Modulation of the CB1 Receptor$624,553
R01 · FY2025 · AA · contact PI
Investigation of Synthetic Cannabinoid Exposures and Pharmacological Consequences$562,088
R01 · FY2025 · DA
Identification of small molecule orexin agonists$107,279
R03 · FY2025 · NS · contact PI
Reducing the post weight-loss energy expenditure gap with orexin agonists$645,968
R01 · FY2024 · DK
Allosteric Modulation of the CB1 Receptor$634,141
R01 · FY2024 · AA · contact PI
Development of LPA5 Antagonists as Analgesics$1,881,741
R61 · FY2023 · NS · contact PI
Reducing the post weight-loss energy expenditure gap with orexin agonists$731,008
R01 · FY2023 · DK
Allosteric Modulation of the CB1 Receptor$681,852
R01 · FY2023 · AA · contact PI
Investigation of Synthetic Cannabinoid Exposures and Pharmacological Consequences$579,418
R01 · FY2023 · DA
Investigation of Synthetic Cannabinoid Exposures and Pharmacological Consequences$567,172
R01 · FY2022 · DA
Allosteric Modulation of the CB1 Receptor$484,537
R01 · FY2020 · DA · contact PI
Allosteric Modulation of the CB1 Receptor$484,537
R01 · FY2019 · DA · contact PI
Allosteric Modulation of the CB1 Receptor$484,537
R01 · FY2018 · DA · contact PI
Allosteric Modulation of the CB1 Receptor$484,537
R01 · FY2017 · DA · contact PI
Allosteric Modulation of the CB1 Receptor$484,537
R01 · FY2016 · DA · contact PI
Orexin-1 Receptor Ligands for Drug Addiction$492,412
R33 · FY2015 · DA · contact PI
Orexin-1 Receptor Ligands for Drug Addiction$499,911
R33 · FY2014 · DA · contact PI
Orexin-1 Receptor Ligands for Drug Addiction$254,132
R21 · FY2013 · DA · contact PI
Orexin-1 Receptor Ligands for Drug Addiction$264,721
R21 · FY2012 · DA · contact PI
Bivalent ligands as molecular probes for CB1/OX1 receptor heterodimers$255,998
R21 · FY2010 · DA · contact PI
Bivalent ligands as molecular probes for CB1/OX1 receptor heterodimers$312,483
R21 · FY2009 · DA · contact PI